Lakshmi Muthuswamy

Lakshmi Muthuswamy

Auto-generated profile, based on publicly available information

Lakshmi Muthuswamy

Blueprint Medicines Corporation, Cambridge, Massachusetts

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JGJoseph E. Grossman
Joseph E. Grossman
LMLakshmi Muthuswamy
Lakshmi Muthuswamy
LHLing Huang
Ling Huang
DADipikaa Akshinthala
Dipikaa Akshinthala
SPSofia Perea
Sofia Perea
MHManuel Hidalgo
Manuel Hidalgo
Purpose: Pancreatic ductal adenocarcinoma (PDAC) remains a significant health issue. For most patients, there are no options for targeted therapy, and existing treatments are limited by toxicity. The HOPE trial (Harnessing Organoids for PErsonalized Therapy) was a pilot feasibility trial aiming to prospectively generate patient-derived organoids (PDO) from patients with PDAC and test their drug sensitivity and correlation with clinical outcomes. Experimental Design: PDOs were established from a heterogeneous population of patients with PDAC including both basal and classical PDAC subtypes. Results: A method for classifying PDOs as sensitive or resistant to chemotherapy regimens was developed to predict the clinical outcome of patients. Drug sensitivity testing on PDOs correlated with clinical responses to treatment in individual patients. Conclusions: These data support the investigation of PDOs to guide treatment in prospective interventional trials in PDAC.

13 February 2025 in Cancer Research
Verified
Journal Article
Open access
NHNealia C. House
Nealia C. House
VBVictoria E. Brown
Victoria E. Brown
MCMaxine Chen
Maxine Chen
LYLiang Yuan
Liang Yuan
SMSydney L. Moore
Sydney L. Moore
KFKerrie L. Faia
Kerrie L. Faia
BLU-222 is an investigational, potent, highly selective, orally bioavailable cyclin-dependent kinase 2 (CDK2) inhibitor in clinical development. BLU-222 demonstrated robust antitumor activity in select CCNE1-high ovarian and endometrial cancer models. We used a combination of CRISPR whole-genome screens coupled with targeted genetic and pharmacologic approaches in ovarian and endometrial cell lines to identify biological determinants to predict BLU-222 monotherapy activity. Rb and p16 expression were biomarkers that enriched for CDK2-dependency/BLU-222 sensitivity in CCNE1-overexpressed, nonamplified cells. Furthermore, intact Rb and low p16 expression predicted a BLU-222 and CDK4/6 inhibitor combination response. BLU-222 demonstrated robust activity in combination with carboplatin or paclitaxel in CCNE1-aberrant models, rendering chemotherapy-resistant tumors strongly sensitive to the combination. These findings demonstrate that response to CDK2 inhibition by BLU-222 can be further predicted using a combinatorial biomarker signature that could refine patient selection criteria in CCNE1-high patients and support clinical development. Significance: The identification of biomarkers of response to the CDK2-selective inhibitor BLU-222 and effective combinations with CDK4/6 inhibitors or chemotherapy could enable precision medicine strategies for CDK2 inhibition in ovarian and endometrial cancer. See related article by Dommer and colleagues, p. 1310


17 June 2026
Verified
Other
Open access
NHNealia C. House
Nealia C. House
VBVictoria E. Brown
Victoria E. Brown
MCMaxine Chen
Maxine Chen
LYLiang Yuan
Liang Yuan
SMSydney L. Moore
Sydney L. Moore
KFKerrie L. Faia
Kerrie L. Faia
Additional BLU-222 and chemotherapy combination studies in mice in vivo.

17 June 2026
Verified
Other
Open access
NHNealia C. House
Nealia C. House
VBVictoria E. Brown
Victoria E. Brown
MCMaxine Chen
Maxine Chen
LYLiang Yuan
Liang Yuan
SMSydney L. Moore
Sydney L. Moore
KFKerrie L. Faia
Kerrie L. Faia
Inhibition or knockdown of CDK4/6 sensitizes CCNE1-high, CDKN2A knockout cells to BLU-222.